Clinical trials: Endocrine Disorder
Type 1 Diabetes Mellitus
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
The purpose of this study is to evaluate consistency of accelerated insulin absorption and onset-of-action and shortened duration of action for bolus insulin infusions after pretreatment with 150 units (U) of Hylenex®…
- Trial name
- NCT01526733
- Testing
- Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Halozyme Therapeutics
Diabetes
A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles
This trial is conducted in Europe. The aim of the trial is to investigate different needle features assessed by comparing insulin aspart Pharmacokinetics profiles (the exposure of the trial drug in the body)
- Trial name
- NCT02594033
- Testing
- insulin aspart
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Wound Surgical, Diabetes
Negative Pressure Wound Therapy Devices in Total Knee Arthroplasty
This study is a single-center, prospective, randomized, open-label clinical trial evaluating three commercially available closed-incision negative pressure wound therapy (ciNPWT) devices: NPseal, PICO, and Prevena, in adult…
- Conditions
- Wound Surgical, Diabetes, Obesity, Chronic Kidney Diseases
- Trial name
- NCT07770633
- Testing
- NP Seal, PICO, Prevena
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Painful Diabetic Neuropathy
A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)
Diabetic peripheral neuropathy (DPN) represents a diffuse symmetric and length-dependent injury to peripheral nerves that has major implications on quality of life (QOL), morbidity, and costs from a public health perspective.
- Trial name
- NCT01556152
- Testing
- GRC 17536 (Medium Dose), GRC 17536 (Low Dose)
- Where
- 2 sites in Germany, United Kingdom
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Type 2 Diabetes, Atherosclerosis
Clopidogrel Versus Cilostazol on Vessels
Diabetes is an increasing cause of atherosclerotic and cardiovascular illnesses in South Korea. The clinical application of ultrasound for measuring carotid intima-media thickness, which helps in early detection and surveillance…
- Trial name
- NCT06402747
- Testing
- Clopidogrel, Cilostazol
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Seoul National University Bundang Hospital
Diabetes Mellitus, Type 2
An Online System to Improve Diabetes Self-Care
The purpose of this study is to see if an online program for patients with diabetes helps patients improve their self-care (how they take their medications, what they eat, how much they exercise, and whether they smoke).
- Trial name
- NCT00119938
- Testing
- Access to online patient portal
- Where
- United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- Robert Wood Johnson Foundation
Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Diseases
Inspire HER: Inspiring the Heart and Emotions for Radical Health
Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group.
- Conditions
- Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Diseases, Hypertension, Diabetes
- Trial name
- NCT06966258
- Testing
- Inspire HER Intervention
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Alabama at Birmingham
Pancreatic Cancer
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to…
- Trial name
- NCT02278458
- Testing
- icotinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Diabetes, Healthy
Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects
This trial is conducted in Asia. The aim of this clinical trial is to investigate the pharmacokinetic properties (the rate at which the trial drug is eliminated from the body) after a single subcutaneous (under the skin)…
- Trial name
- NCT01242826
- Testing
- biphasic insulin aspart 50
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Pancreas Adenocarcinoma, Pancreas Metastases
Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX
This is a prospective, pilot study from a single center. Patients will be evaluated and operated on by one of five surgeons with a subspeciality in hepato-biliary and pancreatic surgery.
- Conditions
- Pancreas Adenocarcinoma, Pancreas Metastases, Pancreas Cancer
- Trial name
- PDAC-LIV (NCT06349278)
- Testing
- Pancreatic resection and non-anatomic liver resections.
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Laval University
Breast Cancer
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
- Trial name
- NCT00166543
- Testing
- TAS-108
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- SRI International
Diabetes Mellitus, Type 2
A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
An open-label, phase II study to assess the acute and chronic effects of empagliflozin (BI 10773)on fasting and postprandial glucose homeostasis in patients with IGT and type 2 diabetes mellitus and assess the acute effects of…
- Trial name
- NCT01248364
- Testing
- BI 10773
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ovarian Epithelial Carcinoma, Fallopian Tube Carcinoma
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
This is a pilot phase, randomized, double-blinded feasibility pilot study of AHCC in participants with ovarian cancer.
- Conditions
- Ovarian Epithelial Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- NCT05763199
- Testing
- AHCC, Chemotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Davis
Diabetes
UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes
The aim is to Investigate the safety and efficacy of Portal vein infusion Allogeneic Human umbilical cord mesenchymal stem cells combined with Allogeneic islet transplantation for the treatment of diabetes
- Trial name
- NCT06751199
- Testing
- human umbilical cord mesenchymal stem cells, allogeneic islet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT06549816
- Testing
- sigvotatug vedotin
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Endometrial Cancer Stage III, Endometrial Cancer Stage IV
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
- Conditions
- Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Endometrial Cancer Recurrent
- Trial name
- PROMOTE (NCT03621904)
- Testing
- Hormonal Antineoplastics
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Radboud University Medical Center
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
- Trial name
- ENDURE (NCT00856284)
- Testing
- Alogliptin, Metformin, Glipizide
- Where
- 261 sites in United States, Argentina and 30 more
- Volunteers
- 2,639 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of DSP-8658 in patients with Type 2 diabetes mellitus and healthy adults.
- Trial name
- NCT01042106
- Testing
- DSP-8658
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients
The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment period.
- Trial name
- EASIE (NCT00751114)
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 17 sites in United States, Austria and 15 more
- Volunteers
- 515 people
- Sponsor
- Sanofi
Diabetic Nephropathy
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria and Moderately Decreased GFR
- Trial name
- NCT01756716
- Testing
- MT-3995 Low, MT-3995 High
- Where
- 50 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 49 people
- Sponsor
- Tanabe Pharma Corporation
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.